BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $96,000 | -17.2% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $116,000 | -15.3% | 1,500 | -6.2% | 0.01% | -16.7% |
| Q4 2021 | $137,000 | -52.1% | 1,600 | -55.0% | 0.01% | -50.0% |
| Q3 2021 | $286,009 | -2.8% | 3,556 | -2.7% | 0.01% | -7.7% |
| Q2 2021 | $294,308 | -4.6% | 3,656 | 0.0% | 0.01% | -23.5% |
| Q1 2021 | $308,347 | -7.5% | 3,656 | -12.0% | 0.02% | -10.5% |
| Q4 2020 | $333,477 | -6.6% | 4,156 | -6.4% | 0.02% | -20.8% |
| Q3 2020 | $357,226 | -6.6% | 4,442 | 0.0% | 0.02% | -20.0% |
| Q2 2020 | $382,456 | +52.0% | 4,442 | +43.3% | 0.03% | +20.0% |
| Q1 2020 | $251,689 | -14.4% | 3,100 | -11.9% | 0.02% | -3.8% |
| Q4 2019 | $294,175 | -4.4% | 3,518 | 0.0% | 0.03% | -13.3% |
| Q3 2019 | $307,719 | +9.0% | 3,518 | +2.0% | 0.03% | +7.1% |
| Q2 2019 | $282,391 | +3.1% | 3,448 | +2.4% | 0.03% | -6.7% |
| Q1 2019 | $273,771 | +69.8% | 3,367 | +37.4% | 0.03% | +42.9% |
| Q4 2018 | $161,259 | -14.6% | 2,450 | 0.0% | 0.02% | 0.0% |
| Q3 2018 | $188,871 | +4.4% | 2,450 | 0.0% | 0.02% | 0.0% |
| Q2 2018 | $180,908 | +3.8% | 2,450 | -8.6% | 0.02% | 0.0% |
| Q1 2018 | $174,307 | +0.6% | 2,680 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $173,235 | +6.6% | 2,680 | +3.5% | 0.02% | 0.0% |
| Q3 2017 | $162,523 | – | 2,590 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |